10.1002/chem.201604633
Chemistry - A European Journal
FULL PAPER
PhSnMe3 (24) was efficiently radiolabeled to yield [18F]FPh in
66% RCC (Fig. 6). Moreover, [18F]DAA1106 ([18F]26), a further
promising PET probe for the visualization of TSPO
expression,[5b] was also prepared from the corresponding stannyl
precursor 25 in an unoptimized RCC of 31%.[22] Finally, we
briefly tested the applicability of the method for conventional
fluorination. Tetramethylammonium fluoride as a fluoride source
afforded 12% HPLC yield of 4-fluoroindole from indole-4-boronic
acid under the same reaction conditions applied for 18F-
labeling.[23]
We have demonstrated the efficient application of alcohols as
co-solvents for Cu-mediated 18F-fluorination. Based on this
finding, we developed a procedure for rapid radiolabeling of a
broad range of substrates such as (hetero)arylboronic acids,
pinacolyl boronates, and trialkylstannanes under general
reaction conditions in many cases in yields of 80–99%. This
[5]
a) J. Zischler, P. Krapf, R. Richarz, B. D. Zlatopolskiy, B. Neumaier,
Appl. Radiat. Isot. 2016, 115, 133-137; b) B. D. Zlatopolskiy, J. Zischler,
P. Krapf, F. Zarrad, E. A. Urusova, E. Kordys, H. Endepols, B.
Neumaier, Chem. Eur. J. 2015, 21, 5972-5979.
[6]
[7]
[8]
[9]
See Reference [2b], Supporting Information S9-10
Please, see SI for the complete details of optimisation studies.
See Supporting Information, Table 1.
Radiochemical conversion (RCC; 18F-incorporation) refer to the amount
of radiofluoride which is transformed to the desired 18F-labeled
compound, determined by radio-HPLC or TLC. Radiochemical yield
(RCY) refers to the isolated yield of the radiochemically and chemically
pure radiolabeled compound. All RCYs are corrected for decay.
[10] All syntheses were carried out manually.
[11] a) J. H. Clark, Chem. Rev. 1980, 80, 429-452; b) In contrast SN2
radiofluorination in tert-BuOH media is well established. For the recent
review, please, see: Lee, J.-W. et al. Hydrogen-bond promoted
nucleophilic fluorination: concept, mechanism and applications in
positron emission tomography. Chem. Soc. Rev. 45, 4638-4650 (2016).
[12] N. K. Kaushik, N. Kaushik, P. Attri, N. Kumar, C. H. Kim, A. K. Verma,
E. H. Choi, Molecules 2013, 18, 6620-6662.
procedure
substantially
simplifies
the
production
of
[18F]fluorinated arenes by removing the time-consuming
azeotropic drying steps. Furthermore, it allows "last-stage"
access to 18F-fluorinated indoles, phenols, and anilines from
unprotected precursors. The preparation of clinical doses of two
PET-tracers, 6-[18F]FDA and 6-[18F]FDOPA demonstrated the
practicality of the method. The suitability of the protocol for
commercially available synthesis modules is currently under
investigation.
[13] a) C. Breda, K. V. Sathyasaikumar, S. Sograte Idrissi, F. M.
Notarangelo, J. G. Estranero, G. G. L. Moore, E. W. Green, C. P.
Kyriacou, R. Schwarcz, F. Giorgini, Proc. Natl. Acad. Sci. USA 2016,
113, 5435-5440; b) J. Chiappelli, T. T. Postolache, P. Kochunov, L. M.
Rowland, S. A. Wijtenburg, D. K. Shukla, M. Tagamets, X. Du, A.
Savransky, C. A. Lowry, A. Can, D. Fuchs, L. E. Hong,
Neuropharmacol. 2016, 41, 2587-2595; c) M. Platten, W. Wick, B. J.
Van den Eynde, Cancer Res. 2012, 72, 5435-5440; d) R. Sandyk, Int. J.
Neurosci. 1992, 67, 127-144; e) R. Sandyk, H. Fisher, Int. J. Neurosci.
1989, 45, 215-219; f) N. Szabó, Z. T. Kincses, J. Toldi, L. Vécsei, J.
Neurol. Sci. 2011, 310, 256-260; g) A. T. van der Goot, E. A. A. Nollen,
Trends Mol. Med 2013, 19, 336-344; h) H. Wakamoto, D. C. Chugani,
C. Juhász, O. Muzik, W. J. Kupsky, H. T. Chugani, Pediatr. Neurol.
2008, 39, 181-188.
Acknowledgements
This work was supported by the DFG grant ZL 65/1-1.
[14] We used the novel method for the preparation of 4-, 5-, 6- and 7-
[
18F]fluorotryptophans (RCCs 90–99%). These probes were prepared
Keywords: copper, fluorination, imaging agents, positron
as ready-to-use solutions in 40–50% isolated yields and with specific
activities of 40–60 GBq/µmol (for 1–2.5 GBq of tracer). Their biological
evaluation is under evaluation and will be reported together with details
of their preparation in due course. For recently published synthesis of
6-[18F]fluorotryptophan, see: D. Schäfer, P. Weiß, J. Ermert, J. Castillo
Meleán, F. Zarrad, B. Neumaier, Eur. J. Org. Chem. 2016, 4621-4628.
[15] a) C. J. D. Austin, J. Kahlert, M. Kassiou, L. M. Rendina, Int. J.
Biochem. Cell Bio, 2013, 45, 1212-1216; b) F. Roncaroli, Z. Su, K.
Herholz, A. Gerhard, F. E. Turkheimer, Clin. Transl. Imaging 2016, 4,
145-156; c) R. Rupprecht, V. Papadopoulos, G. Rammes, T. C. Baghai,
J. Fan, N. Akula, G. Groyer, D. Adams, M. Schumacher, Nat. Rev. Drug
Discovery 2010, 9, 971-988.
emission tomography, radiopharmaceuticals
[1]
a) A. F. Brooks, J. J. Topczewski, N. Ichiishi, M. S. Sanford, P. J. Scott,
Chem. Sci. 2014, 5, 4545-4553; b) L. Cai, S. Lu, V. W. Pike, Eur. J. Org.
Chem. 2008, 2853-2873; c) O. Jacobson, L. Zhu, Y. Ma, I. D. Weiss, X.
Sun, G. Niu, D. O. Kiesewetter, X. Chen, Bioconjugate Chem. 2011, 22,
422-428; d) M. Tredwell, V. Gouverneur, Angew. Chem. 2012, 124,
11590-11602; Angew. Chem., Int. Ed. 2012, 51, 11426-11437.
[2]
a) A. S. Kamlet, C. N. Neumann, E. Lee, S. M. Carlin, C. K. Moseley, N.
Stephenson, J. M. Hooker, T. Ritter, PLoS One 2013, 8, e59187; b) E.
Lee, J. M. Hooker, T. Ritter, J. Am. Chem. Soc. 2012, 134, 17456-
17458; c) E. Lee, A. S. Kamlet, D. C. Powers, C. N. Neumann, G. B.
Boursalian, T. Furuya, D. C. Choi, J. M. Hooker, T. Ritter, Science 2011,
334, 639-642; d) B. D. Zlatopolskiy, J. Zischler, E. A. Urusova, H.
Endepols, E. Kordys, H. Frauendorf, F. M. Mottaghy, B. Neumaier,
ChemistryOpen 2015, 4, 457-462.
[16] T. Keller, A. M. Kryczmonik, S. Forsback, A. Kirjavainen, F. Lopez-
Picon, C. F., A. Damont, F. Dolle, M. Haaparanta, O. Solin, J. Label.
Compd. Radiopharm. 2015, 58, S75-S411.
[17] A. Damont, F. Caille, V. Medran-Navarrete, F. Cacheux, B. Kuhnast, F.
Dolle, J. Label. Compd. Radiopharm. 2015, 58, S180.
[3]
a) N. Ichiishi, A. F. Brooks, J. J. Topczewski, M. E. Rodnick, M. S.
Sanford, P. J. Scott, Org. Lett. 2014, 16, 3224-3227; b) A. V. Mossine,
A. F. Brooks, K. J. Makaravage, J. M. Miller, N. Ichiishi, M. S. Sanford,
P. J. H. Scott, Org. Lett. 2015, 17, 5780-5783; c) S. Preshlock, S.
Calderwood, S. Verhoog, M. Tredwell, M. Huiban, A. Hienzsch, S.
Gruber, T. C. Wilson, N. J. Taylor, T. Cailly, M. Schedler, T. L. Collier, J.
Passchier, R. Smits, J. Mollitor, A. Hoepping, M. Mueller, C. Genicot, J.
Mercier, V. Gouverneur, Chem. Commun. 2016, 52, 8361-8364; d) M.
Tredwell, S. M. Preshlock, N. J. Taylor, S. Gruber, M. Huiban, J.
Passchier, J. Mercier, C. Genicot, V. Gouverneur, Angew. Chem., Int.
Ed. 2014, 53, 7751-7755; Angew. Chem. 2014, 126, 7885-7889.
R. Richarz, P. Krapf, F. Zarrad, E. A. Urusova, B. Neumaier, B. D.
Zlatopolskiy, Org. Biomol. Chem. 2014, 12, 8094-8099.
[18] a) D. Taieb, H. Neumann, D. Rubello, A. Al-Nahhas, B. Guillet, E.
Hindie, J. Nucl. Med. 2012, 53, 264-274; b) H. J. L. M. Timmers, G.
Eisenhofer, J. A. Carrasquillo, C. C. Chen, M. Whatley, A. Ling, K. T.
Adams, K. Pacak, Clin. Endocrinol. 2009, 71, 11-17.
[19] a) S. Balogova, J.-N. Talbot, V. Nataf, L. Michaud, V. Huchet, K. Kerrou,
F. Montravers, Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 943-966; b) V.
Berti, A. Pupi, L. Mosconi, Ann. N. Y. Acad. Sci. 2011, 1228, 93-108; c)
V. L. Cropley, M. Fujita, R. B. Innis, P. J. Nathan, Biol. Psychiatry 2006,
59, 898-907; d) C. Juhasz, S. Dwivedi, D. O. Kamson, S. K.
Michelhaugh, S. Mittal, Mol. Imaging 2014, 13, 1-16; e) M. Politis, Nat.
Rev. Neurol. 2014, 10, 708-722; f) A. Varrone, C. Halldin, J. Nucl. Med.
2010, 51, 1331-1334.
[4]
This article is protected by copyright. All rights reserved.